FRANK M. LAFERLA, PH.D. Curriculum Vitae CURRENT APPOINTMENTS: Director, Institute for Memory Impairments and Neurological Disorders Fellow, Center for the Neurobiology of Learning & Memory, UCI July 28, 1963 USA 3 Vega Court Irvine, CA 92617 (949) 466-­‐3380 PERSONAL INFORMATION: Date of Birth: Citizenship: Home address: EDUCATION: 1981-­‐1985 1985-­‐1987 1987-­‐1990 PROFESSIONAL EXPERIENCE: 2011 – present 2009 – present 2005 – present Chancellor’s Professor (with tenure) Chair, Department of Neurobiology and Behavior University of California, Irvine 3212 Biological Sciences III Irvine, CA 92697-­‐4545 Tel: (949) 824-­‐1232 Fax: (949) 824-­‐7356 Email: [email protected] B.S. Ph.D. St. Joseph’s University (Philadelphia, PA) Thomas Jefferson Medical College (Philadelphia, PA) University of Minnesota (Minneapolis, MN) Advisor: Dr. Richard W. Peluso Chair, Neurobiology and Behavior Director, Institute for Memory Impairments and Neurological Disorders (UCI MIND) Professor 1
2003 – 2007 2001 – 2005 1995 – 2001 1990 -­‐ 1995 HONORS AND AWARDS: Director, Interdepartmental Neuroscience Program Associate Professor Assistant Professor Department of Neurobiology and Behavior University of California, Irvine Irvine, CA 92697-­‐4545 F. M. Firby Postdoctoral Fellow Department of Virology Jerome H. Holland Laboratory, American Red Cross Rockville, MD Advisor: Dr. Gilbert Jay 1981 -­‐ 1985 1985 1987 1990 1995 1995 1998 1999 2001
University Presidential Scholarship, St. Joseph’s University Sigma Xi, St. Joseph's University First place, Student Poster, American Society for Microbiology F. M. Firby/Cancer Research Institute Fellow Young Scientist Travel Grant (Calgary, Italy) American Red Cross ReCIP Award UCI nominee for Pew Scholar Award Ratio Imaging System Prize (Intracellular Imaging Inc.) Ruth Salta Junior Investigator Achievement Award in Alzheimer’s Disease from the American Health Assistance Foundation 2005 Distinguished Mid-­‐career Faculty Award for Research (UCI) 2005 – 2008 Chancellor’s Fellow, UCI 2005 Zenith Fellow Award, Alzheimer’s Association 2005 UCI Faculty Innovation Award 2006 Distinguished Lecture, Allergan Foundation Lectures in Modern Biology 2006 Promising Work Award, MetLife Foundation Awards for Medical Research 2007 Distinguished Lecture on Learning and Memory, Barclay Theater, Irvine 2007 John Theobald Memorial Lecture, Arizona Alzheimer’s Consortium 2008 Jan Swammerdam Lecture, Netherlands Institute for Neuroscience 2008 Chancellor’s Professor, UCI 2008 Plenary Lecture, International Conference on Alzheimer’s Disease 2010 UCI Daniel G. Aldrich Jr. Distinguished University Service Award 2010 Fellow, American Association for the Advancement of Science 2011 Elected Member, American Neurological Association PROFESSIONAL SOCIETIES: American Association for Advancement of Science American Neurological Association 2
American Society for Cell Biology International Society for Stem Cell Research Society for Neuroscience JOURNAL /EDITORIAL REVIEW SERVICE: EDITORIAL BOARD: •Current Alzheimer Research (Associate Editor) •Neurobiology of Aging AD HOC REVIEWER:
•American Journal of Pathology •Nature Genetics •Annals of Neurology •Nature Medicine •Biochemistry •Nature Neuroscience •Biological Psychiatry •Nature Reviews Drug Discovery •Brain Pathology •Nature Reviews Molecular Cell •European Journal of Neuroscience Biology •Experimental Neurology •Nature Reviews Neuroscience •FASEB Journal •Neurobiology of Aging •Journal of Biological Chemistry •Neurobiology of Disease •Journal of Cell Biology •Neurobiology of Learning & •Journal of Clinical Investigation Memory •Journal of Molecular Neuroscience •Neuron •Journal of Neurochemistry •Neuroscience •Journal of Neuroscience •Neuroscience Letters •Lancet •New England Journal of Medicine •Molecular and Cellular •Proceedings of the National Neuroscience Academy of Sciences U.S.A. •Molecular Neurobiology •Science •Nature •Trends in Molecular Medicine •Nature Cell Biology •Trends in Neuroscience GRANT REVIEW COMMITTEES: AD HOC SERVICE: 1997 University of Michigan Geriatrics Center & Institute of Gerontology 1998 Comitato Telethon Fondazione Onlus– Combatti la distrofia musclare e le altre malattie genetiche (Italian Telethon Foundation) 1998 -­‐ 03 Alzheimer's Disease Association 2000 -­‐ 03 Italian Ministry for Universities and Research 2000 University of California System Wide BioSTAR Program 2000 Manitoba Medical Service Foundation 3
2001
Veterans Affairs Grant Review Service 2002
UK Alzheimer’s Association 2003
AFAR National Scientific Advisory Council 2003 Institute for the Study of Aging Scientific Review Board 2003 NIH, Program Project Evaluation Panel 2004 NIH Reverse Site Visit 2005 NIH Study Section (NINDS) 2005-­‐present ISOA review board 2006-­‐2009 NIH, Program Project Evaluation Panel 2007-­‐present AFAR National Scientific Advisory Council REGULAR MEMBER SERVICE: 1999 -­‐ 2003 Brain Disorders and Clinical Neuroscience-­‐3 (ZRG1 BDCN-­‐3) Study Section, National Institutes of Health 2006-­‐present Cell Death in Neurodegeneration (CDIN) Study Section, National Institutes of Health CURRENT GRANT FUNDING: TR1-­‐01245 08/09-­‐07/12 1.20 calendar CIRM $1.2 million (direct per year) “Neural stem cells as a developmental candidate to treat Alzheimer’s disease” The goal of this grant is to determine whether human neural stem cells or human ES cells can be adapted as a therapy for the treatment of Alzheimer’s disease. R01 AG-­‐027544 (LaFerla) 04/07-­‐03/12 1.20 calendar NIH/NIA $250,000 “Learning and Memory Impairments in a Transgenic AD Model with Plaques and Tangles” The goal of this project is to elucidate the molecular pathways by which learning and memory is affected in the 3xTg-­‐AD mice. This study involves a 2-­‐year longitudinal analysis of the cognitive phenotype, as well as determining the effect of prior learning or ongoing cognitive stimulation on the neuropathological and behavioral phenotype. R01 AG-­‐021982 (LaFerla) 07/08-­‐06/13 1.20 calendar NIH/NIA $225,000 “Gene Interactions in a Model of Alzheimer’s Disease” 4
The goal of this project is to investigate the gene interactions that underlie the pathogenesis of Alzheimer’s disease. We will determine how various gene interactions (e.g., tau alone, tau + ßAPP, tau + ßAPP + PS1) influence the development of AD neuropathology. We will identify the molecular determinants (e.g., soluble vs. insoluble Aß, tau hyperphosphorylation) and gene interactions (tau, PS1, or ßAPP) that underlie the synaptic dysfunction. NIA 2P50AG016573-­‐11 (Cotman/LaFerla) 04/02/10-­‐03/31/11 .48 calendar $1,242,005.00 “ADRC of UCI” CURRENT OTHER SUPPORT SONEXA THERAPEUTICS INC. (LaFerla) 10/02/09-­‐09/30/10 .60
calendar $343,739 “Therapeutic Administration of ST101: Evaluation in a Transgenic Mouse Model with both Plaques and Tangles” The goal of the proposed studies is to evaluate the therapeutic potential of the novel cognitive enhancer ST101 in a novel ripple transgenic mouse model of Alzheimer’s Disease (3xTg-­‐AD) that expresses both plaque and tangle pathology. ABBOTT LABORATORIES (LaFerla) 12/31/08-­‐12/31/10 1.8 Calendar $289,447 “Effect of Abbott a7 agonist on AD Neuropathology and Cognition in 3xTg-­‐AD Mice” The goal of this study will be to assess whether a selective a7 agonist can ameliorate Or reverse the Aß and tau neuropathology and cognitive phenotype in the 3xTg_AD mouse model. PLEXXIKON (LalFerla) 01/01/10-­‐12/31/11 .84 calendar $349,752 “Administration of Plexxikon compound: Evaluation in Transgenic Mouse Models with both Plaques and Tangles and with Selective Neuronal Loss” The goal of this project is to evaluate therapeutic potential of Plexxikon’s FMS inhibitor in a novel triple transgenic mouse model of Alzheimer’s Disease (3xTg-­‐AD) that expresses both plaques and tangle pathology as well as a novel mouse model of selective neuronal loss (CAMKII/Tet) GERON/UC DISCOVERY (LaFerla) 11/01/09-­‐01-­‐31/11 .36 calendar $153,000 5
“Treating Alzheimer’s Disease with Human Stem Cells (GRNOPC1)” The aims of this project are to evaluate therapeutic potential of GRNOP1 to rescue the cognitive deficits in two mouse models of neurodegeneration. AMERICAN HEALTH ASSISTANCE FOUNDATION (AHAF) (LaFerla) 4/1/10-­‐3/31/13 $400,000 “BDNP-­‐mediated Treatment for Neurodegenerative Disease” The goal of the proposal is to test the hypothesis that BDNF is an essential component of the mechanism by which NSC transplantation mediated cognitive recovery in transgenic models of Alzheimer’s Disease and hippocampal neuronal death. PRIVATE DONATIONS: Anonymous donation of $70,000 Provided through the Neurosciences Education and Research Foundation, 9/99 Anonymous donation of $100,000 Provided in May, 2006 Anonymous donation of $125,000 Provided in July 2010 GRANT AWARD MENTOR: K-­‐AWARDS: K01AG029378 ROLE OF APP ASSEMBLY STATES IN TAU PATHOLOGY AND COGNITIVE DECLINE PI: Mathew Blurton-­‐Jones K01-­‐DK-­‐73032 LIVER SVCT SYSTEMS: VITAMIN C UPTAKE, ROLES AND REGULATION P.I: Jack Reidling NIH K99A054695 PATHOGENIC ROLE OF APP, TAU AND INFLAMMATION IN INCLUSION BODY MYOSITIS 6
PI: Masashi Kitazawa NIH K99AG029729 MOLECULAR MECHANISMS OF MEMORY LOSS IN A TRANSGENIC MODEL OF ALZHEIMER DISEASE PI: Salvatore Oddo NRSA AWARDS: F31AG026852 CELL LOSS IN AN ALZHEIMER’S DISEASE MODEL WITH PLAQUES AND TANGLES PI: Debbie Morrissette F31NS063659 THE IMPACT OF ISCHEMIA ON ALZHEIMER’S DISEASE Maya Koike 1F31AGO034061-­‐01A1 INVESTIGATING THE ROLE OF BDNF IN THE STEM CELL-­‐MEDIATED RESTORATION OF COGNITION P.I: Nicholas Castello 5F31NS066649-­‐02 DETERMINING THE FUNCTIONAL ROLE OF ADULT NEUROGENESIS P.I: Kristoffer Myczek GRANT FUNDING HISTORY: P50 AG16573 (Cotman: PI, LaFerla: Project leader) 04/05-­‐03/10 1.20 calendar NIH/NIA $125,000 "Effect of Aß Immunotherapy on Tau Aggregates" The goals of this project are determine whether Aß immunotherapy will suffice to halt the progression of tau pathology in the brains of the 3xTg-­‐AD mice. CIRM (LaFerla) 7/1/07-­‐6/30/09 $492,000 “Modeling Alzheimer Disease in Human Embryonic Stem Cells” 1.20 calendar 7
The goal of this project is to use human embryonic stem cells to create a cell-­‐culture model of Alzheimer's disease that mirrors the complex array of human proteins involved in this devastating condition. He then plans to use these cells to perform a screen of more than 7,300 genes to identify promising new drug targets that may slow the progression of Alzheimer’s disease. NIH R01 AG-­‐021982 GENE INTERACTIONS IN A MODEL OF ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 07/03-­‐06/08 Total direct cost: $225,000/YR Alzheimer’s Association Zenith Fellow’s Award AD-­‐ZEN-­‐05-­‐14836 LEARNING & MEMORY DEFICITS IN A MOUSE MODEL WITH PLAQUES & TANGLES PI: F. M. LaFerla Dates: 09/05-­‐06/07 Total direct costs: $125,000/YR NIH R01 AG20335 MODULATING IBM PATHOLOGY IN TRANSGENIC MICE PI: F. M. LaFerla Dates: 3/02-­‐2/06 Total cost: $250,000/YR NIH R01 AG17968. REGULATION OF CALCIUM SIGNALING PATHWAYS BY PRESENILINS PI: F. M. LaFerla Dates: 7/01-­‐6/06 Total cost: $225,000/YR Alzheimer’s Association IIRG02-­‐3767. A NOVEL TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 7/02-­‐6/05 Total cost: $240,000 NIH P50-­‐AG16573. PRESENILIN FUNCTION AND CALCIUM REGULATION IN ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 4/00-­‐3/05 Total cost: $503,959 UCI Parkinson’s Disease Task Force INDUCIBLE GENETIC ABLATION OF CATECHOLAMINERGIC NEURONS: A NOVEL TRANSGENIC MODEL OF PARKINSON’S NEURODEGENERATION PI: F. M. LaFerla Dates: 7/02-­‐6/03 Total cost: $50,000 NIH R29-­‐AG15409. TRANSGENIC MOUSE MODEL OF INCLUSION BODY MYOSITIS PI: F. M. LaFerla Dates: 4/98-­‐3/03 Total cost: $503,959 American Health Assistance Foundation A2000005. CALCIUM DYSHOMEOSTASIS INDUCED BY PRESENILIN MUTATIONS PI: F. M. LaFerla Dates: 4/00-­‐3/02 Total cost: $180,000 8
Alzheimer’s Association IIRG99-­‐1758. ROLE OF HERPES SIMPLEX VIRUS AS A COFACTOR IN ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 9/99-­‐8/01 Total cost: $119,998 BioSTAR CAPACITATIVE CALCIUM ENTRY AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE PI: M. Cahalan Dates: 3/02-­‐2/03 Total cost: $100,000 Co-­‐PI: F. M. LaFerla American Federation for Aging Research P00101. MOLECULAR DETERMINANTS OF PRESENILINS IN INTRACELLULAR CALCIUM SIGNALING PATHWAY PI: F. M. LaFerla Dates: 7/00-­‐12/01 Total cost: $50,000 California 98-­‐15717. INVESTIGATIONS INTO THE ROLE OF THE NEUROTROPIC HERPES SIMPLEX VIRUS TYPE-­‐1 IN ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 1/99-­‐12/00 Total cost: $150,000 NIH R03-­‐AG14508. TRANSGENIC MOUSE MODEL OF INCLUSION BODY MYOSITIS PI: F. M. LaFerla Dates: 2/97-­‐1/98 Total cost: $74,950 NIH R03-­‐AG14864. ROLE OF VIRAL COFACTOR IN SPORADIC ALZHEIMER’S DISEASE PI: F. M. LaFerla Dates: 7/97-­‐6/98 Total cost: $74,950 NIH P50-­‐AG05142. ADRC Consortium of Los Angeles and Orange County Caleb Finch, USC, Director/Carl Cotman, UCI, Sub-­‐project IN VITRO AND IN VIVO CHARACTERIZATION OF THE PRESENILIN-­‐1 GENE IN AD Project leader: F.M. LaFerla Dates: 5/96-­‐3/97 Total cost: $20,000 Markey-­‐ Pilot Project Investigator. Carl Cotman and Ian Lipkin, Project Directors HERPESVIRUS GLYCOPROTEINS AND ALZHEIMER’S DISEASE Project leader: F.M. LaFerla Dates: 5/96-­‐2/97 Total cost: $10,000 Markey-­‐ Pilot Project Investigator. Carl Cotman and Ian Lipkin, Project Directors DEVELOPMENT OF A TRANSGENIC MODEL OF INCLUSION BODY MYOSITIS Project leader: F.M. LaFerla Dates: 2/98-­‐1/99 Total cost: $15,000 PATENTS: 9
U.S. Provisions Application Serial #6-­‐/451,381: filed Feb 28, 2003 “SK-­‐31B Transgenic Mouse Model for Spinocerebellar Ataxia and Hyperexcitable Behavior” U.S. Patent Application Serial #10/288,138 “Transgenic Mouse Model of Inclusion Body Myositis” U.S. Patent Application Serial #10/499,269 “Triple Transgenic Mouse Model of Alzheimer’s Disease” PUBLICATIONS: ORIGINAL REPORTS: 1. Watrous, J. J. and LaFerla, F. M. (1984). Measurement of the interaction between Chrsyaora quinquecirrha (sea nettle) toxin and rat liver inner mitochondrial membranes. Annals of the New York Academy of Sciences 1, 225-­‐229. 2. LaFerla, F. M. and Peluso, R. W. (1989). The N-­‐NS protein complex of vesicular stomatitis virus is essential for efficient genome replication. Journal of Virology 63, 3852-­‐3857. 3.
LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C., and Jay, G. (1995). The Alzheimer’s Aß peptide induces neurodegeneration and apoptosis in transgenic mice. Nature Genetics 9, 21-­‐30. 4.
Cribbs, D. H., Chen, L.-­‐S., Bende, S. M., and LaFerla, F. M. (1996). Widespread neuronal expression of presenilin-­‐1 early-­‐onset Alzheimer’s disease gene in the murine brain. American Journal of Pathology 148, 1797-­‐1806. 5.
Cribbs, D. H., Chen, L.-­‐S., Cotman, C. W., and LaFerla, F. M. (1996). Injury induces presenilin-­‐1 gene expression in mouse brain. NeuroReport 7, 1773-­‐1776. 6.
LaFerla, F. M., Hall, C. K., Ngo, L., and Jay, G. (1996). Extracellular deposition of the ß-­‐
amyloid peptide upon p53-­‐dependent neuronal cell death in transgenic mice. Journal of Clinical Investigation 98, 1626-­‐1632. 7.
LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H., and Jay, G. (1997). Neuronal cell death in Alzheimer’s disease correlates with apoE uptake and intracellular Aß stabilization. Journal of Clinical Investigation 100, 310-­‐320. 8.
Weber, L. M., Leissring, M. A., Yang, A. J., Glabe, C. G., Cribbs, D. H., and LaFerla, F. M. (1997). Presenilin-­‐1 immunoreactivity is localized intracellularly in Alzheimer’s disease brain, but not detected in amyloid plaques. Experimental Neurology 143, 37-­‐44. 10
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Leissring, M. A., Sugarman, M. C., and LaFerla, F. M. (1998). Herpes simplex virus infection and Alzheimer’s disease: implications for drug and immunotherapy. Drugs and Aging 13, 193-­‐198. (Leading Article). Leissring, M. A., Paul, B., Parker, I., Cotman, C. W., and LaFerla, F. M. (1999). Alzheimer’s presenilin-­‐1 mutation potentiates inositol 1,4,5-­‐trisphosphate-­‐mediated calcium signaling in Xenopus oocytes. Journal of Neurochemistry 72, 1061-­‐1068. LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H., and Jay, G. (1997). Neuronal cell death in Alzheimer’s disease correlates with apoE uptake and intracellular Aß stabilization. Journal of Clinical Investigation 100, 310-­‐320. Leissring, M. A., Parker, I., and LaFerla, F. M. (1999). Presenilin-­‐2 mutations modulate amplitude and kinetics of inositol 1,4,5-­‐trisphosphate-­‐mediated calcium signals. Journal of Biological Chemistry 274, 32535-­‐32538. Cribbs, D. H., Azizeh, B. A., Cotman, C. W., and LaFerla, F. M. (2000). Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer’s ß-­‐amyloid peptide. Biochemistry 39, 5988-­‐5994. Leissring, M. A., Akbari, Y., Fanger, C. M., Cahalan, M., Mattson, M. P., and LaFerla, F. M. (2000). Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-­‐1 knock-­‐in mice. Journal of Cell Biology 149, 793-­‐798. Leissring, M. A., Yamasaki, T. R., Wasco, W., Buxbaum, J. D., Parker, I., and LaFerla, F. M. (2000). Calsenilin reverses presenilin-­‐mediated enhancement of calcium signaling. Proceedings of the National Academy of Sciences, U.S.A. 97, 8590-­‐8593. LaFerla, F. M., Sugarman, M. C., Lane, T. E., and Leissring, M. A. (2000). Regional hypomyelination and dysplasia in transgenic mice with astrocyte-­‐directed expression of interferon-­‐gamma. Journal of Molecular Neuroscience 15, 45-­‐59. Mattson, M. P., LaFerla, F. M., Chan, S. L., Leissring, M. A., Shepel, P. N., and Geiger, J. D. (2000). Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences 23, 222-­‐229. Leissring, M. A., LaFerla, F. M., Callamaras, N., and Parker, I. (2001). Subcellular mechanisms of presenilin-­‐mediated enhancement of calcium signaling. Neurobiology of Disease 8, 469-­‐478. Marchant, J. S., Stutzmann, G. E., Leissring, M. A., LaFerla, F. M., and Parker, I. (2001). Multiphoton-­‐evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling. Nature Biotechnology 19, 645-­‐649. 11
20.
21.
22.
Sugarman, M. S., Yamasaki, T. R., Oddo, S., Echegoyen, J. C., Murphy, M. P., Golde, T.E., Jannatipour, M., Leissring, M. A., and LaFerla, F. M. (2002). Inclusion body myositis-­‐
like phenotype induced by transgenic overexpression of ßAPP in skeletal muscle. Proceedings of the National Academy of Sciences, U.S.A. 99, 6334-­‐6339. Leissring, M. A., Murphy, M. P., Mead, T. R., Akbari, Y., Sugarman, M. C., Jannatipour, M., Anliker, B., Müller, U., Saftig, P., De Strooper, B., Wolfe, M. S., Golde, T. E., and LaFerla, F. M. (2002). A physiologic signaling role for the g-­‐secretase-­‐derived intracellular fragment of APP. Proceedings of the National Academy of Sciences, U.S.A., 99, 4697-­‐4702. LaFerla, F. M. (2002). Calcium dyshomeostasis and intracellular signaling in Alzheimer’s disease. Nature Reviews Neuroscience 3, 862-­‐872. 23.
24.
25.
26.
27.
28.
29.
Stutzmann, G. E., LaFerla, F. M., Parker, I. (2003). Ca2+ signaling in mouse cortical neurons studied by two-­‐photon imaging and photoreleased inositol triphosphate. Journal of Neuroscience 23, 758-­‐765. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. (2003). Triple transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aß and synaptic dysfunction. Neuron 39, 409-­‐421. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B., and LaFerla, F. M. (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiology of Aging 24, 1063-­‐1070. Shakkottai,V. G., Chou, C-­‐H., Oddo, S., Sailer, C. A., Knaus, H.-­‐G., Gutman, G. A., Barish, M. E., LaFerla, F. M., and Chandy, K. G. (2004). Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. Journal of Clinical Investigation 113, 582-­‐590. Stutzmann, G. E., Caccamo, A., LaFerla, F. M., and Parker, I. (2004). Dysregulated IP3-­‐ signaling in cortical neurons of knock-­‐in mice expressing an Alzheimer’s linked mutation in presenilin-­‐1 result in exaggerated Ca2+ signals and altered membrane excitability. Journal of Neuroscience 24, 508-­‐513. Tseng, B., Kitazawa, M., LaFerla, F. M. (2004). Amyloid ß-­‐Peptide: The Inside Story. Current Alzheimer Research 1, 231-­‐239. Rissman, R. A., Poon, W. W., Blurton-­‐Jones, M., Oddo, S., Torp, R., LaFerla, F. M., Rohn, T. T., and Cotman, C. W. (2004). Caspase-­‐cleavage of tau is an early event in 12
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
neurofibrillary pathology in Alzheimer’s disease. Journal of Clinical Investigation 114, 121-­‐130. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., and LaFerla, F. M. (2004). Aß immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-­‐332. Kitazawa, M., Yamasaki, T. R., and LaFerla, F. M. (2004). Microglia as a bridge between amyloid ß-­‐peptide and tau. Annals of the New York Academy of Sciences 1035, 85-­‐103 Akbari, Y., Hitt, B., Murphy, M. P., Dagher, N. N., Tseng, B. P., Green, K. N., Golde, T. E., and LaFerla, F. M. (2004). Presenilin regulates capacitative calcium entry dependently and independently of g-­‐secretase activity. Biochemical Biophysical Research Communication 322, 1145-­‐1152. Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y., and LaFerla, F. M. (2005). Age-­‐ and region-­‐dependent alterations in ß-­‐amyloid degrading enzymes (neprilysin and insulin degrading enzyme): implications for Aß-­‐related disorders. Neurobiology of Aging 26, 645-­‐654. LaFerla, F. M. and Oddo, S. (2005). Alzheimer’s disease: Aß, tau, and synaptic dysfunction. Trends in Molecular Medicine 11, 170-­‐176. Oddo, S., Caccamo, A., Green, K., Liang, K., Tran, L., Chen, Y., Leslie, F. M., and LaFerla, F. M. (2005). Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer’s disease. Proceedings of the National Academy of Sciences, USA 102, 3046-­‐3051. Billings, L., Oddo, S., Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2005). Intraneuronal Aß causes the onset of early Alzheimer’s disease-­‐related cognitive deficits in transgenic mice. Neuron 45, 675-­‐688. Smith, I. F., Hitt, B., Green, K. N., Oddo, S., and LaFerla, F. M. (2005). Enhanced caffeine-­‐
induced Ca2+release in the 3xTg-­‐AD model of Alzheimer’s disease. Journal of Neurochemistry 94, 1711-­‐1718. Smith, I. F., Green, K. N., and LaFerla, F. M. (2005). Calcium dysregulation in Alzheimer’s disease: recent advances gained from genetically-­‐modified animals. Cell Calcium 38, 427-­‐437. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and LaFerla, F. M. (2005). LPS-­‐
induced inflammation exacerbates tau pathology by a cdk5-­‐mediated pathway in a transgenic model of Alzheimer’s disease. Journal of Neuroscience 25, 8843-­‐8853. 13
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Janelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., and Bowers, W. J. (2005). Early correlation of microglial activation with enhanced tumor necrosis factor-­‐alpha and monocyte chemoattractant protein-­‐1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. Journal of Neuroinflammation 2, 23-­‐35. LaFerla, F. M. and Kitazawa, M. (2005). Antipodal effects of p25 on synaptic plasticity, learning and memory — too much of a good thing is bad. Neuron 48, 711-­‐712. LaFerla, F. M. (2006). An array of genes implicated in Alzheimer’s disease: a commentary. Neurobiology of Aging 27, 1078-­‐1080. Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., and LaFerla, F. M. (2006). A dynamic relationship between intracellular and extracellular pools of Aß. American Journal of Pathology 168, 184-­‐194. Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., and LaFerla, F. M. (2006). Temporal profile of Aß oligomerization in an in vivo model of Alzheimer disease: a link between Aß and tau pathology. Journal of Biological Chemistry 281, 1599-­‐1604. Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-­‐Coria, H., Fisher, A., and LaFerla, F. M. (2006). M1 receptors play a central role in modulating AD-­‐like pathology in transgenic mice. Neuron 49, 671-­‐682. Kitazawa, M., Green, K. N., Caccamo, A., and LaFerla, F. M. (2006). Genetically augmenting Aß42 levels in skeletal muscle exacerbates inclusion body myositis-­‐like pathology and motor deficits in transgenic mice. American Journal of Pathology 168, 1986-­‐1997. Sugarman, M. C., Kitazawa, M., Querfurth, H., Baker, M., Caizzo, V., and LaFerla, F. M. (2006). Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiology of Aging 27, 423-­‐32. Moussa, C. E-­‐H., Fu, Q., Kumar, P., Shtifman, A., Lopez, J. R., Allen, P. D., LaFerla, F. M., Weinberg, D., Magrane, J., Aprahamian, T., Walsh, K., Rosen, K., and Querfurth, H. W. (2006). Transgenic expression of ß-­‐APP in fast-­‐twitch skeletal muscle leads to calcium dyshomeostasis and IBM-­‐like pathology. FASEB J. 20, 1570-­‐78. Oddo, S. and LaFerla, F. M. (2006). The role of nicotine receptors in Alzheimer’s disease. Journal of Physiology (Paris) 99, 172-­‐179. 14
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
Stutzmann, G. E., Smith, I., Caccamo, A., Oddo, S., LaFerla, F. M., and Parker, I. (2006). Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer’s disease mice. Journal of Neuroscience 26, 5180-­‐5189. Heredia, L., Helguera, P., de Olmos, S., Kedikian, G., Sola Vigo, F., LaFerla, F. M., Staufenbiel, M., de Olmos, J., Busciglio, J., Caceres, A., and Lorenzo, A. (2006). Phosphorylation of actin-­‐depolymerizing factor/cofilin by LIM-­‐kinase mediates amyloid ß-­‐induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer´s disease. Journal of Neuroscience, 26, 6533-­‐42. Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., and LaFerla, F. M. (2006). Glucocorticoids increase amyloid-­‐ß and tau pathology in a mouse model of Alzheimer’s disease. Journal of Neuroscience 26, 9047-­‐9056. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., and LaFerla, F. M. (2006). Reduction of soluble Aß and tau, but not soluble Aß alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. Journal of Biological Chemistry 281, 39413-­‐23. Rosario, E. R., Carroll, J. C., Oddo, S., LaFerla, F. M., and Pike, C. J. (2006). Androgens regulate development of neuropathology in a triple transgenic model of Alzheimer’s disease. Journal of Neuroscience 26, 13384-­‐89. Lahiri, D.K., and LaFerla, F. M. (2006). Alzheimer’s Disease: A Centennial Issue. Current Alzheimer Research 3, 409-­‐410. Blurton-­‐Jones, M. and LaFerla, F. M. (2006). Pathways by which Aß facilitates tau pathology. Current Alzheimer Research 3, 437-­‐48. Billings, L. M. and Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2007). Learning decreases Aß*56 and tau pathology and ameliorates behavioral decline in 3xTg-­‐AD mice. Journal of Neuroscience 27, 751-­‐761. Halagappa, V. K., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., LaFerla, F. M., and Mattson, M. P. (2007). Intermittent fasting and caloric restriction ameliorate age-­‐
related behavioral deficits in the triple-­‐transgenic mouse model of Alzheimer’s disease. Neurobiology of Disease 26, 212-­‐220. Gimenez-­‐Llort L., Blazquez G., Canete T., Johansson B., Oddo S., Tobena A., LaFerla F.M., and Fernandez-­‐Teruel A. (2007). Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neuroscience & Biobehavioral Reviews 31, 125-­‐47. 15
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Matsuoka, Y., Gray, A. J., Hirata-­‐Fukae, C., Minami, S. S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., and Aisen, P. S. (2007). Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage. Journal of Molecular Neuroscience 31, 165-­‐170. Caccamo, A., Oddo, S., Tran, L. X., and LaFerla, F. M. (2007). Lithium reduces tau phosphorylation but not Aß or working memory deficits in a transgenic model with both plaques and tangles. American Journal of Pathology 170, 1669-­‐1775. Green, K. N., Martinez-­‐Coria, H., Khashwji, H., Hall, E. B., Yurko-­‐Mauro, K., Ellis, L., and LaFerla, F. M. (2007). Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-­‐beta and tau pathology via a mechanism involving presenilin 1 levels. Journal of Neuroscience 27, 4385-­‐95. Oddo, S., Caccamo, A., Cheng, D., Jouleh, B., Torp, R., and LaFerla, F. M. (2007). Genetically augmenting tau levels does not modulate the onset or progression of Aß pathology in transgenic mice. Journal of Neurochemistry 102, 1053-­‐1063. Stutzmann, G. E., Smith, I., Caccamo, A., Oddo, S., Parker, I., and LaFerla, F. M. (2007). Enhanced ryanodine-­‐mediated calcium release in mutant PS1-­‐expressing Alzheimer’s mouse models. Annals New York Academy of Sciences 1097, 265-­‐77. Tseng, B. P., Green, K. N., Chan, J. L., Blurton-­‐Jones, M., and LaFerla, F. M. (2008). Aß inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiology of Aging 29, 1607-­‐1618. LaFerla, F. M., Green, K. N., and Oddo, S. (2007). Intracellular amyloid-­‐ß in Alzheimer’s disease. Nature Reviews Neuroscience 8, 499-­‐509. Cole, A. R., Noble, W., van Aalten, L., Plattner, F., Meimaridoi, R., Hogan, D. Taylor, M., Gunn-­‐Moore, F., Verkhratsky, A., Oddo, S., LaFerla, F., Giese, K. O., Dineley, K. T., Richardson, J. C., Yan, S. D., Hanger, D. P., Allan, S. M., and Sutherland, C. (2007). Collapsin response mediator protein-­‐2 hyperphosphorylatoin is an early event in Alzheimer’s disease progression. Journal of Neurochemistry 103, 1132-­‐1144. Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, Oddo, S., LaFerla, F. M., and Pike, C. J. (2007). Progesterone and estrogen regulate Alzheimer-­‐like neuropathology in female 3xTg-­‐AD mice. Journal of Neuroscience 27, 11357-­‐11365. Takata, K., Hirata-­‐Fukae, C., Becker, A. G., Chishiro, S., Gray, A. J., Nishitomi, K., Franz, A. H., Sakaguchi, G., Kato, A., Mattson, M. P., LaFerla, F. M., Aisen, P. S., and Yasuji Matsuoka, Y. (2007). Deglycosylated anti-­‐amyloid beta antibodies reduce microglial 16
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. European Journal of Neuroscience 26, 2458-­‐2468. Maezawa, I., Hong, H.-­‐S., Liu, R., Wu, C.-­‐Y., Cheng, R. H., Kung, M.-­‐P., Kung, H. F., Lam, K. S., Oddo, S., LaFerla, F. M., and Jin, L.W. (2008). Congo red and thioflavin-­‐T analogs detect Aß oligomers. Journal of Neurochemistry, 104, 457-­‐568. Clinton, L. K., Billings, L. M., Green, K. N., Caccamo, A., Ngo, J., Oddo, S., McGaugh, J. L., and LaFerla, F. M. (2007). Age-­‐dependent sexual dimorphism in cognition and stress response in the 3xTg-­‐AD mice. Neurobiology of Disease 28, 76-­‐82. Yamasaki, T. R., Blurton-­‐Jones, M., Morrissette, D. A., Kitazawa, M., Oddo, S., and LaFerla, F. M. (2007). Neural stem cells improve memory in an inducible mouse model of neuronal loss. Journal of Neuroscience 27, 11925-­‐11933. Green, K. N., Smith, I. F., and LaFerla, F. M. (2007). Role of calcium in the pathogenesis of Alzheimer’s disease and transgenic models. Subcellular Biochemistry 45, 507-­‐21. Lopez, J. R., Lyckman, A., Oddo, S., LaFerla, F. M., Querfurth, H. W., and Shtifman, A. Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice. (2008). Journal of Neurochemistry 105, 262-­‐271. Kitazawa, M., Trinh, D., and LaFerla, F. M. (2008). Inflammation induces tau hyperphosphorylation in a mouse model of inclusion body myositis via a mechanism involving glycogen synthase kinase-­‐3ß. Annals of Neurology 64, 15-­‐24. Hirata-­‐Fukae, C., Li, H.-­‐F., Ma, L., Hoe, H.-­‐S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Takenouchi, H., Tsukagoshi-­‐Nagai, H., Horikoshi-­‐Sakuraba, Y., Rebeck, G. W.. LaFerla, F. M., Mattson, M. P., Iwata, N., Klein, W. L., Duff, K., Aisen, P. S., and Yasuji Matsuoka, Y. (2008). Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Research 1216, 92-­‐103. McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., and Dedeoglu, A. (2008). Ibuprofen reduces Aß, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Research 1207, 225-­‐236. Green, K. N., Demuro, A., Akbari, Y., Hitt, B. D., Smith, I. F., Parker, I., and LaFerla, F. M. (2008). SERCA pump activity is physiologically regulated by presenilin and regulates Aß production. Journal of Cell Biology 181, 1107-­‐1116. Nakashima, A. S., Oddo, S., LaFerla, F. M., and Dyck, R. H. (2008). Experience-­‐
dependent regulation of vesicular zinc in male and female 3xTg-­‐AD mice. Neurobiology of Aging, 4, 605-­‐13 17
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Oddo, S., Caccamo, A., Cheng, D., and LaFerla, F. M. (2008). Genetically altering Abeta distribution from the brain to the vasculature amerliorates tau pathology. Brain Pathology, in press. Green, K. N. and LaFerla, F. M. (2008). Linking calcium to Aß and Alzheimer’s disease. Neuron 59, 190-­‐194. Rodriguez, J. J., Jones, V. C., Tabuchi, M., Allan, S. M., Knight, E. M., LaFerla, F. M., Oddo, S., and Verkhratsky, A. (2008). Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS ONE 3, e2935. Jamelsins, M. C., Mastrangelo, M. A., Park, K. M., Sudol, K. L., Narrow. W. C., Oddo, S., LaFerla, F. M., Callahan, L. M., Federoff, H. J., and Bowers, W. J. (2009). Chronic neuron-­‐specific tumor necrosis factor-­‐alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-­‐AD mice. American Journal of Pathology 173, 1768-­‐1782. Knuesel, I., Nyffeler, M., Mormede, C., Muhia, M., Meyer, U., Pietropaolo, S. B., Yee, B. K. Pryce, C., LaFerla, F. M., Marighetto, A., Feldon, J. (2009). Age-­‐related accumulation of Reelin in amyloid-­‐like plaques. Neurobiology of Aging 103, 1132-­‐1144. Gulinello, M., Gertner, M., Mendoza, G., Schoenfeld, B. P., Oddo, S., LaFerla, F. M., Choi, C. H., McBride, S. M., and Faber, D. S. (2008). Validation of a 2-­‐day water maze protocol in mice. Behav. Brain Research 196, 220-­‐227. Lopes, J. P., Blurton-­‐Jones, M., Yamasaki, T. R., Agostinho, P., and LaFerla, F. M. (2008). Activation of cell cycle proteins in transgenic mice in response to neuronal cell loss but not Aß or tau pathology. Journal of Alzheimer’s Disease 16, 541-­‐549. Green, K. N., Steffan, J. S., Martinez-­‐Coria, H., Schreiber, S. S., Thompson, L. M., and LaFerla, F. M. (2008). Nicotinamide, an inhibitor of the sirtuins, reduces tau pathology and restores cognition in Alzheimer’s disease transgenic mice. Journal of Neuroscience 28, 11500-­‐11510. Oddo, S., Caccamo, A., Tseng, B., Cheng, D., Vasilevko, V., Cribbs, D. H., and LaFerla, F. M. (2008). Blocking Aß42 accumulation delays the onset and progression of tau pathology and cognitive decline via CHIP: A mechanistic link between Aß and tau pathology. Journal of Neuroscience 28, 12163-­‐12175. Morrissette, D. A., Parachikova, A., Green, K. N., and LaFerla, F. M. (2008). Relevance of transgenic mouse models to human Alzheimer disease. J. Biol. Chem. 284, 6033-­‐6037. 18
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
Guan, H., Liu, Y., Daily, A., Police, S., Kim, M. H., Oddo, S., LaFerla, F. M., Pauly, J. R., Murphy, M. P., and Hersh, L. B. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer’s disease. Journal of Neuroscience Research 87, 1462-­‐1473. Nuntagij, P., Oddo, S., LaFerla, F. M., Kotchabhakdi, N., Otterson, O. P., and Torp , R. (2009). Amyloid deposits show complexity and initimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-­‐AD mice and aged canines. Journal of Alzheimer’s Disease 16, 315-­‐323. Kitazawa, M., Cheng, D., and LaFerla, F. M. (2009). Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. Journal of Neurochemistry 108, 1550-­‐1556. McAlpine, F.E., Lee, J. K., Harms, A. S., Ruhn, K.A., Blurton-­‐Jones, M., Hong, J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., Blesch, A., and Tansey, M. G. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-­‐plaque amyloid associated neuropathology. Neurobiology of Disease 34, 163-­‐177. Caccamo, A., Fisher, A., and LaFerla, F. M. (2009). M1 agonists as a potential disease-­‐
modifying therapy for Alzheimer’s disease. Current Alzheimer Disease 6, 112-­‐117. Bourasset, F., Oullet, M., Tremblay, C., Julien, C., Do, T. M., Oddo, S., LaFerla, F. M., and Calonc, F. (2009). Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer’s disease. Neuropharmacology, 56, 808-­‐813. Shtifman, A., Ward, C. W., Laver, D. R., Bannister, M. L., Lopez, J. R., Kitazawa, M., LaFerla, F. M., Ikemoto, N., Querfurth, H. W. (2008). Neurobiology of Aging, doi:10.1016/j.neurobioaging.2008.11.003 Kitazawa, M., Vasilevko, V., Cribbs, D. H., and LaFerla, F. M. (2009). Immunization with amyloid-­‐beta attenuates inclusion body myositis-­‐like myopathology and motor impairment in a transgenic mouse model. Journal of Neuroscience 29, 6132-­‐6141. Fonseca, M. I., Ager, R., R,. Chu, S-­‐H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., and Tenner, A. J. (2009). Treatment with a C5aR Antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer disease. Journal of Immunology 183, 1375-­‐1383. Blurton-­‐Jones, M., Kitazawa, M., Martinez-­‐Coria, H., Muller, F. J., Loring, J. F., Poon, W. W., Green, K. N., and LaFerla, F. M. (2009). Neural stem cells rescue cognition by increasing synaptic density in Alzheimer disease mice via a neurotrophic mechanism. Proc. Natl. Acad. Sci, USA, 106, 13594-­‐13599. 19
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
Espana, J., Gimenez-­‐Llort, L., Valero, J., Minano, A., Rodriguez-­‐Alvarez, J., LaFerla, F. M., and Saura, C. A. (2009). Intraneuronal Aß accumulation is associated with enhanced fear and anxiety in transgenic mouse models of Alzheimer’s disease. Biol. Psychiatry 67, 513-­‐521 Aiken, C. T., Steffan, J. S., Guerrero, C. M., Khashwji, H., Lukacsovich, T., Simmons, D., Purcell, J. M., Menhaji, J., Zhu, Y.-­‐Z., Green, K., LaFerla, F. M., Huang, L., Thompson, L. M., and Marsh, L. (2009). Phosphorylation of threonine-­‐3: implications for huntingtin aggregation and neurotoxicity. Journal of Biological Chemistry, 284:29427-­‐36. Robertson, R. T., Baratta, J. Yu, J., LaFerla, F. M. (2009). Amyloid-­‐beta expression in retrosplenial cortex of triple transgenic-­‐Alzheimer’s disease mice: relationship to cholinergic axonal afferents from medial septum. Neuroscience, 164: 1334-­‐46. Bianchi, S. L., Caltagarone, B. M., LaFerla, F. M., Eckenhoff, R. G., Kelz, M. B. (2009). Inhaled anesthetic potency in aged Alzheimer mice. Anesth. Analg., in press. Martinez-­‐Coria, H., Green, K. N., Billings, L. M., Kitazawa, M., Bannerjee, P., and LaFerla, F. M. (2010). Memantine as a pathology and cognitive modifying therapeutic for Alzheimer’s disease. American Journal of Pathology 176, 870-­‐880. Bryleva, E. Y., Rogers, M. A., Chang, C. C. Y., Buen, F., Harris, B. T., Rousselet, E., Seidah, N. G., Oddo, S., LaFerla, F. M., Spencer, T. A., Hickey, W. F., and Chang, T. Y. (2010). Inactivation of acyl-­‐CoA:cholesterol acyltransferase 1 Increases 24S-­‐hydroxycholesterol and ameliorates amyloid pathology in AD mice. Proc. Natl. Acad. Sci., USA, 107, 3081-­‐
3086 Querfurth, H. W. and LaFerla, F. M. (2010). Alzheimer’s disease. New England Journal of Medicine 362, 329-­‐344. Thompson, L.M., Aiken, C.T., Kaltenbach, L.S., Agrawal, N., Illes, K., Khoshnan, A., Martinez-­‐Vincente, M., Arrasate, M., O'Rourke, J.G., Khashwji, H., Lukacsovich, T., Zhu, Y.Z., Lau, A.L., Massey, A., Hayden, M.R., Zeitlin, S.O., Finkbeiner, S., Green, K.N., LaFerla, F.M., Bates, G., Huang, L., Patterson, P.H., Lo, D.C., Cuervo, A.M., Marsh, J.L., and Steffan J.S. (2009). IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. Journal of Cell Biology 187, 1083-­‐1099. Koike, M., Green, K. N., Blurton-­‐Jones, M., and LaFerla, F. M. (2010). Oligomeic hypoperfusion differentially affects tau and amyloid-­‐beta. American Journal of Pathology 177, 300-­‐310 Clinton, L. K., Blurton-­‐Jones, M., Myczek, K., Trojanowski, J. Q., and LaFerla, F. M. (2010). Synergistic interaction between Aß, tau, and a-­‐synuclein: acceleration of neuropathology and cognitive decline. Journal of Neuroscience 30, 7281-­‐7289. 20
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
Medeiros, R., Baglietto-­‐Vargas, D., and LaFerla, F. M. (2010). The role of tau in Alzheimer’s disease and related disorders. CNS Neuroscience Therapeutics, in press. Parachikova, A., Vislevko, V., Cribbs, D. H., LaFerla, F. M., and Green, K. N. (2010). Reductions in amyloid-­‐ß derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. Journal of Alzheimer’s Disease, 21(2), 527-­‐542 Sterniczuk, R., Antie, M. C., LaFerla, F. M., and Dyck, R. H. (2010). Characterization of the 3xTg-­‐AD mouse model of Alzheimer’s disease: part 2. Behavioral and cognitive changes. Brain Research 1348, 149-­‐155. LaFerla, F. M. (2010). Pathways linking Aß and tau pathologies. Biochemical Society Transactions 38, 993-­‐995. Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M., and Valla, J. (2010). Regional cerebral glucose uptake in 3xTg model of Alzheimer’s disease highlights common regional vulnerability across AD models. Brain Research 1347, 179-­‐
185. Blanchard, J., Wanka, L., Tung, Y. C., Cardenas-­‐Aguayo, M. D., LaFerla, F. M., Iqbal, K., and Grudke-­‐Iqbal, I. (2010). Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aß and tau pathologies in 3xTg-­‐AD mice. Acta Neuropathologica, Online First 8/9/10. Parachikova, A., Green, K. N., Hendrix, C., and LaFerla, F. M. (2010). Formulation of a medical food cocktail for the treatment of Alzheimer’s disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PloS One 5, e14015. Piedrahita, D., Herndez, I., Lopez-­‐Tob, A., Fedorov, D., Obara, B., Manjunath, B.S., Boudreau, R., Davidson, B., LaFerla, F., Gallego-­‐Gomez, J.C., Kosik, K., and Cardona-­‐
Gomez, G. P. (2010). Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice. Journal of Neuroscience 30, 13966-­‐13976. Garcia, Y., Lopez-­‐Ramos, J. C., Gimenez-­‐Llort, L., Revilla, S., Guerra, R., Gruart, A., LaFerla, F. M., Cristofol, R., Delgado-­‐Garcia, J. M., and Sanfeliu, C. (2011). Physical exercise protects against Alzheimer’s disease in 3xTg-­‐AD mice. Journal of Alzheimer’s Disease. Journal of Alzheimer’s Disease 23, 1-­‐34. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX (2011) BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-­‐
onset axon terminal pathology. Neurotox Res. 2012 Feb;21(2):160-­‐74. Epub 2011 Jul 2. 21
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
PMID: 21725719 Bianchi FT, Camera P, Ala U, Imperiale D, Migheli A, Boda E, Tempia F, Berto G, Bosio Y, Oddo S, LaFerla FM, Taraglio S, Dotti CG, Di Cunto F. (2011) The collagen chaperone HSP47 is a new interactor of APP that affects the levels of extracellular beta-­‐amyloid peptides. PLoS One. 2011;6(7):e22370. Epub 2011 Jul 28. PMID: 21829458 Chou, J., Shenoy, D. W., Thomas, N., Choudhary, P. K., LaFerla, F. M., Goodman, S. R., Breen, G. A. M. (2011). Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer’s disease. Journal of Proteomics, in press. Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S. M., Hoffman, N., Mitteregger, G, Kretzchmar, H., LaFerla, F. M., and Herms, J. (2011). Multiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice. PloS One 5, e15477. Lin, A. J., Koike, M. A., Green, K.N., Kim, J. G., Mazhar, A., Rice, T. B., LaFerla, F. M., and Tromberg, B. J. (2011). Annals. Biomedical Engineering, in press. Neely, K. M., Green, K. N., and LaFerla, F. M. (2011). Presenilin is necessary for efficient proteolysis through the autophagy-­‐lyososome system in a γ-­‐secretase independent manner. Journal of Neuroscience 31, 2781-­‐2791. Green, K.N., Kahshwji, H., Estrada, T., LaFerla, F.M. (2011) ST101 induces a novel 17kDa APP cleavage that precludes Aß generation in vivo. Annals of Neurology 69, 831-­‐844. (PMID:21416488). Koike M.A., Garcia, F.G., Kitazawa, M., Green K.N., LaFerla, F.M. (2011) Long-­‐term changes in phospho-­‐APP and tau aggregation in the 3xTg-­‐AD mice following cerebral ishchemia. Neuroscience Letters PMID:21419194 Garin, D., Oukhatar, F., Mahon, A.B., Try, A.C., Dubois-­‐Dauphin, M., LaFerla, F.M., Demeunynck, M., Sallanon, M.M., Chierici, S. (2011) Proflavine deritivitives as fluorescent imaging agents of amylpoid deposits. Bio-­‐organic Medicine Chemical Letters, 8, 203-­‐6. PMID: 21435875 Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, Motomura K, Soejima N, Yamasaki R, Hashimoto T, Tabira T, LaFerla FM, Kira J.(2011) Apomorphine treatment in Alzheimer mice promoting amyloid-­‐β degradation. Ann Neurol. Feb;69(2):248-­‐56. doi: 10.1002/ana.22319. PMID: 21387370 Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, LaFerla FM. (2011) Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol. 178, 2811-­‐22. PMID: 21531375 22
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
Freude KK, Penjwini M, Davis JL, LaFerla FM, Blurton-­‐Jones M. (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem. 2011 Jul 8;286(27):24264-­‐74. Epub 2011 May 23. PMID:21606494 Alonso E, Vale C, Vieytes MR, Laferla FM, Giménez-­‐Llort L, Botana LM.(2011) The cholinergic antagonist gymnodimine improves Aβ and tau neuropathology in an in vitro model of Alzheimer disease.Cell Physiol Biochem. 2011;27(6):783-­‐94. Epub 2011 Jun 17. PMID: 21691095 Medeiros R, Kitazawa M, Caccamo A, Baglietto-­‐Vargas D, Estrada-­‐Hernandez T, Cribbs DH, Fisher A, LaFerla FM. (2011) Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-­‐like pathology and cognitive decline. Am J Pathol. Aug;179(2):980-­‐
91. Epub 2011 Jun 23. PMID:21704011 Coskun P, Wyrembak J, Schriner S, Chen HW, Marciniack C, LaFerla F, Wallace D.C. (2011) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta. 2011 Aug 16. [Epub ahead of print] PMID:21871538 Alonso E, Vale C, Vieytes MR, Laferla FM, Giménez-­‐Llort L, Botana LM.(2011) 13-­‐
Desmethyl spirolide-­‐C is neuroprotective and reduces intracellular Aβ and Neurochem Int. Aug 30. [Epub ahead of print]PMID:21907746 Tang JX, Mardini F, Caltagarone BM, Garrity ST, Li RQ, Bianchi SL, Gomes O, LaFerla FM, Eckenhoff RG, Eckenhoff MF. (2011) Anesthesia in presymptomatic Alzheimer's disease: a study using the triple-­‐transgenic mouse model. Alzheimers Dement. Sep;7(5):521-­‐
531.e1. doi: 10.1016/j.jalz.2010.10.003. Epub 2011 Jul 13.PMID:21745760. Medeiros R, Baglietto-­‐Vargas D, LaFerla FM. (2011) The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther. 2011 Oct;17(5):514-­‐24. doi: 10.1111/j.1755-­‐5949.2010.00177.x. Epub 2010 Jun 14.PMID:20553310 Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, Bellanti F, Laconca L, Romano AD, Padalino I, LaFerla FM, Nicoletti F, Cuomo V, Vendemiale G. (2011) Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging. Oct 27. [Epub ahead of print]PMID:22035587 Cassano T, Romano A, Macheda T, Colangeli R, Cimmino CS, Petrella A, LaFerla FM, Cuomo V, Gaetani S. (2011) Olfactory memory is impaired in a triple transgenic model of Alzheimer disease. Behav Brain Res. Oct 31;224(2):408-­‐12. Epub 2011 Jun 30. PMID:21741995. Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P.D., Vailevko, V., Cribbs, D. H., and LaFerla, F. M. (2011). Blocking IL-­‐1 signaling rescues cognition, attenuates tau 23
140.
141.
142.
143.
144.
pathology, and restores neuronal ß–catenin pathway function in an Alzheimer’s disease model. Journal of Immunology 187, 6539-­‐6549. Walker, M. P., LaFerla, F. M., Oddo, S., Brewer, G. J. (2012). Reversible epigenetic histone modifications and BDNF expression in neurons with aging and from a mouse model of Alzheimer’s disease. Age, [Epub ahead of print]. PMID: 22237558. Kitazawa, M., Medeiros, R., LaFerla, F. M. (2012). Transgenic mouse models of Alzheimer’s disease: developing a better model as a tool for therapeutic interventions. Curr. Pharm. Des. 18: 1131-­‐47. Alonso, E., Fuwa, H., Vale, C., Suga, Y., Goto, T., Konno, Y., Sasaki, M., LaFerla, F. M., Vieytes, M. R., Gimenez-­‐Llort, L., and Botana, L. M. (2012). Design and synthesis of skeletal analogues of gambierol: attenuation of amyloid-­‐ß and tau pathology with voltage-­‐gated potassium channel and N-­‐methyl-­‐D-­‐aspartate receptor implications. J. Am. Chem. Soc. [Epub ahead of print]. PMID: 22475455. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, LaFerla FM, Shoji M, Matsubara E. (2012)Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways. Life Sci. 2012 May 3. [Epub ahead of print] PMID: 22579764 Medeiros R, Chabrier MA, LaFerla FM. (2012)Elucidating the Triggers, Progression, and Effects of Alzheimer's Disease.J Alzheimers Dis. 2012 May 24. [Epub ahead of print] PMID: 22635105 145.
146.
147.
Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-­‐Vargas D, Kling A, Moeller A, Green KN, LaFerla FM.(2012) Calpain inhibitor A-­‐705253 mitigates Alzheimer's disease-­‐like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 2012 Aug;181(2):616-­‐25. Epub 2012 Jun 9. PMID: 22688056 Walls KC, Coskun P, Gallegos-­‐Perez JL, Zadourian N, Freude K, Rasool S, Blurton-­‐Jones M, Green KN, LaFerla FM. (2012) Swedish Alzheimer Mutation Induces Mitochondrial Dysfunction Mediated by HSP60 Mislocalization of Amyloid Precursor Protein (APP) and Beta-­‐Amyloid. J Biol Chem. 2012 Aug 31;287(36):30317-­‐27. Epub 2012 Jun 29. Girão da Cruz MT, Jordão J, Dasilva KA, Ayala-­‐Grosso CA, Ypsilanti A, Weng YQ, LaFerla FM, McLaurin J, Aubert I. (2012) Early Increases in Soluble Amyloid-­‐β Levels Coincide with Cholinergic Degeneration in 3xTg-­‐AD mice.J Alzheimers Dis. 2012 Jul 9. [Epub ahead of
print] PMID: 22776965 148.
Wolf AB, Braden BB, Bimonte-­‐Nelson H, Kusne Y, Young N, Engler-­‐Chiurazzi E, Garcia AN, Walker DG, Moses GS, Tran H, LaFerla F, Lue L, Emerson Lombardo N, Valla J. (2012) 24
149.
150.
151.
152.
153.
154.
155.
156.
Broad-­‐Based Nutritional Supplementation in 3xTg Mice Corrects Mitochondrial Function and Indicates Sex-­‐Specificity in Response to Alzheimer's Disease Intervention. J Alzheimers Dis. 2012 Jan 1;32(1):217-­‐32. PMID: 22796872 Rasool S, Albay R 3rd, Martinez-­‐Coria H, Breydo L, Wu J, Milton S, Misra S, Tran A, Pensalfini A, LaFerla F, Kayed R, Glabe C. (2012) Vaccination with a non-­‐human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice.Mol Neurodegener. 2012 Aug 6;7(1):37. [Epub ahead of print] PMID: 22866920 Castello NA, Green KN, LaFerla FM. (2012) Genetic knockdown of brain-­‐derived neurotrophic factor in 3xTg-­‐AD mice does not alter Aβ or tau pathology. PLoS One. 2012;7(8):e39566. Epub 2012 Aug 3. PMID: 22870188 LaFerla FM. (2012) Preclinical success against Alzheimer's disease with an old drug. N Engl J Med. 2012 Aug 9;367(6):570-­‐2. No abstract available. PMID: 22873540 Koike MA, Lin AJ, Pham J, Nguyen E, Yeh JJ, Rahimian R, Tromberg BJ, Choi B, Green KN, LaFerla FM.(2012) APP Knockout Mice Experience Acute Mortality as the Result of Ischemia. PLoS One. 2012;7(8):e42665. Epub 2012 Aug 9. PMID: 22912719 Soejima N, Ohyagi Y, Nakamura N, Himeno E, Iinuma KM, Sakae N, Yamasaki R, Tabira T, Murakami K, Irie K, Kinoshita N, LaFerla FM, Kiyohara Y, Toru I, Kira JI.(2012) Intracellular Accumulation of Toxic Turn Amyloid-­‐β is Associated with Endoplasmic Reticulum Stress in Alzheimer's disease. Curr Alzheimer Res. 2012 Aug 30. [Epub ahead of print] PMID: 22950910 Guzmán-­‐Ramos K, Moreno-­‐Castilla P, Castro-­‐Cruz M, McGaugh JL, Martínez-­‐Coria H, LaFerla FM, Bermúdez-­‐Rattoni F.(2012) Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease.Learn Mem. 2012 Sep 14;19(10):453-­‐60. doi: 10.1101/lm.026070.112. PMID: 22984283 Chakravarthy B, Gaudet C, Ménard M, Brown L, Atkinson T, LaFerla FM, Ito S, Armato U, Dal Prà I, Whitfield J.(2012) Reduction of the immunostainable length of the hippocampal dentate granule cells' primary cilia in 3xAD-­‐transgenic mice producing human Aβ(1-­‐42) and tau.Biochem Biophys Res Commun. 2012 Sep 17. pii: S0006-­‐291X(12)01796-­‐2. doi: 10.1016/j.bbrc.2012.09.056. [Epub ahead of print] PMID: 22995307 Solé-­‐Domènech S, Sjövall P, Vukojević V, Fernando R, Codita A, Salve S, Bogdanović N, Mohammed AH, Hammarström P, Nilsson KP, LaFerla FM, Jacob S, Berggren PO, Giménez-­‐Llort L, Schalling M, Terenius L, Johansson B.(2012) Localization of cholesterol, amyloid and glia in Alzheimer's disease transgenic mouse brain tissue using time-­‐of-­‐
flight secondary ion mass spectrometry (ToF-­‐SIMS) and immunofluorescence imaging. 25
Acta Neuropathol. 2012 Sep 21. [Epub ahead of print] PMID: 22996963 157. LaFerla FM, Green KN. Animal Models of Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Sep 21. pii: cshperspect.a006320v1. doi: 10.1101/cshperspect.a006320. [Epub ahead of print] PMID: 230020 BOOK FOREWORDS: Book foreword: “The Silverado Story”, authors: Shook, L. and Winner, S. (2010) Publisher: AJC Press, Irvine, CA ISBN:978-­‐0-­‐9845337-­‐5-­‐6 Book foreword: “Memories in the Making: a Creative Art Activity for People with Alzheimer’s Disease”, author: Heinly, L. D. Sam. (2010) Publisher: Heinly, L.D. Sam BOOK CHAPTERS: 1.
LaFerla, F. M., Vogel, J., and Jay, G. (1991). Mechanism of human immunodeficiency virus pathogenesis in transgenic mice. AIDS Research Reviews 1, 247-­‐263. 2.
LaFerla, F. M., Huang, T., Bieberich, C. J., and Jay, G. (1995). A transgenic strategy for studying viral pathogenesis, pp. 89-­‐105. In Strategies in Transgenic Animal Science, ed. by Glenn M. Monastersky and James M. Robl. ASM Press, Washington, D.C. 3.
LaFerla, F. M. and Jay, G. (1997). ß-­‐amyloid induced neuronal cell death in transgenic mice and Alzheimer’s disease. In Neuromethods: Apoptosis techniques and protocols, pp. 183-­‐195. Edited by Judes Poirier. Humana Press, Totowa, NJ. 4.
Sugarman, M. C., Hinton, S., and LaFerla, F. M. (2000). Transgenic models of Alzheimer’s disease, pp. 51-­‐72. In Neurodegenerative diseases, (Marie-­‐Francois-­‐Cheeselet, Ed). Humana Press, Totowa, NJ. 5.
Oddo, S. and LaFerla, F. M. (2005). Amyloid plaques and neurofibrillary tangles in a triple transgenic model: qualitative similarities to human Alzheimer’s neuropathology, pp. 111-­‐116. In Recent progress in Alzheimer’s and Parkinson’s diseases. Edited by Israel Hanin, Ramon Cacabelos, and Abraham Fisher. 6.
Green, K. N., Smith, I. F., and LaFerla, F. M. (2007). Role of calcium in the pathogenesis of Alzheimer’s disease and transgenic models. In Calcium Signalling and Disease. Edited by Ernesto Carafoli and Marisa Brini. Springer Books, New York. 26
7.
8.
9.
10.
Koike, M.A., Myczek, K., Green, K.N. and LaFerla, F.M. (2007) Impact of Aβ and tau on cognition in mouse models of Alzhiemer’s Disease. In Animal Models of Human Cognitive Aging. Edited by Alisa Woods and Jennifer Bizon. Humana Press, Totawa, New Jersey. Blurton-­‐Jones, M., Yamasaki, T. R., and LaFerla, F. M. (2008). Improving Memory with Stem Cell Transplantation. In Regulatory Networks in Stem Cells. Edited by Mohan Vemuri and V. K. Rajasekhar. Humana/Springer, New York. Sy, M., Kitazawa, M., LaFerla, F.M. (2010) The 3xTg-­‐AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology. In Animal Models of Dementia Edited by R.Ragavia. Springer/Global Chabrier, M.A., Neely, K.M., Castello, N.A., LaFerla, F.M. (2010) The Contribution of Transgenic Models to the Understanding of Alzheimer Disease Progression and Therapeutic Development. In Animal Models in Neurodegeneration. Edited by Avila J., Hernandez, F., and Lucas, J.J. Royal Society of Chemistry, U.K. PROFESSIONAL ARTICLES ABOUT MY WORK: Alzheimer Research Forum News, Aug 4th (2010). Neuroregeneration Taps Glia, Neurotrophins. Stem Book, June 5th (2010). Stem Cells as Potential Vehicles for Drug Delivery. Alzheimer Research Forum News, May 30th (2010). Triple Trouble: AD Mice Decline Faster With Lewy Bodies. Alzheimer Research Forum News, July 27th (2009). Neural Stem Cell BDNF Prompts Memory in AD Mice. Alzheimer Research Forum News, May 15th (2009). A-­‐beta Immunotherapy – Muscling in on Inclusion Body Myositis. New Scientist, Nov 8th (2007). Stem Cell Shots Restore Lost Memory. Scientific American, Nov 1st (2007). Bystander stem cells keep original neurons humming, restore memory. USA Today, Nov 2nd (2007). Stem Cells May Restore Memory after Brain Damage U.S. News and World Report, Oct 31st (2007). Stem cells restore memory in mice. 27
A triple transgenic scores a home run. Nature Medicine 12, 762-­‐ 763 (2006). Highly cited research papers on Alzheimer disease published in 2003 Nature Medicine 12, 754 (2006) Highly cited research papers on Alzheimer disease published in 2004 Nature Medicine 12, 757 (2006) Highly cited research papers on Alzheimer disease published in 2005 Nature Medicine 12, 759 (2006) Recent papers of Alzheimer disease identified by leaders in the field as notable advances Nature Medicine 12, 767 (2006) Journal of Neuroscience 27, 4385-­‐4395 (2007). Treating the lesions, not the disease. American Journal of Pathology 170, 1457-­‐1479 (2007). Alzheimer's Disease: A New Take on Tau. Science 316, 1416-­‐1417 (2007) http://www.alzforum.org/images/new/LaFerla1460.pdf Drug shows promise for treatment of Alzheimer’s disease. Lancet Neurology 5, 300 (2006). Nicotine exacerbates tau pathology. Lancet Neurology 4, 214-­‐215. Nicotine No Remedy for Alzheimer’s. Science News Briefs (3/15/2007). Drug found to reverse the ravages of Alzheimer’s disease in mice. Scientific American.com (2006) Stopping Alzheimer’s: Antibody thwarts disease in mice. Science News, 7/15, p.38) Clearing tau pathology with Aß immunotherapy —reversible and irreversible stages revealed. Neuron 43, 293-­‐299 (2004). Untangling Alzheimer’s by paring plaques bolsters amyloid theory. Science 305, 762 (2004). Stopping Alzheimer’s: antibody thwarts disease in mice. Science News 7, 166 (2004). 28
Mouse model provides support for amyloid-­‐cascade hypothesis. Lancet (Neurology) 3, 576 (2004). Hyperexcitability induces ataxia. Nature Reviews Neurocience 5, 259 (2004). Mighty mouse. Nature Reviews Neurocience 4, 701 (2003). Cell signaling – a job for AICD. Nature Reviews Neurocience 3, 329 (2002). CLINICAL TRIALS Data from Green et al., 2007 contributed to the clinical trial of DHA for Alzheimer's disease (http://clinicaltrials.gov/ct2/show/NCT00440050?term=dha+alzheimers&rank=1). Data from Green et al., 2008 was solely used to bring nicotinamide to a clinical trial conducted at UCI by Dr. Steven Schrieber (http://clinicaltrials.gov/ct2/show/NCT00580931?term=nicotinamide&rank=11). INVITED PRESENTATIONS: INVITED PRESENTATIONS AT UNIVERSITIES, RESEARCH INSTITUTES OR PHARMACEUTICAL COMPANIES: 2/89 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Invited by Dr. William Haseltine 3/94 National Institute of Child Health and Development (NIH), Bethesda, MD Invited by Dr. Andres Buonanno 2/95 Department of Neurology, University of Pittsburgh School of Medicine Invited by: Dr. Roger Simon 6/95 Wyeth-­‐Ayerst Research, Princeton, NJ Invited by Dr. Louis DeGennaro 2/96 Clinical Neuroscience Grand Rounds, UCI Invited by Dr. Patrick Kesslak 5/96 Orange County Alzheimer’s Disease Association, Beckman Institute Invited by Elizabeth Long Palmer, Alzheimer’s Association 5/97 3rd Annual Canine Cognition, Aging & Neuropathology Meeting, UCI Invited by Dr. Elizabeth Head 29
5/97 6/97 5/98 Center for the Neurobiology of Learning and Memory, Spring Mtg., UCI Invited by Dr. James L. McGaugh Schlering-­‐Plough Research Institute, Keniliworth, NJ Invited by Dr. Eric Parker Center for the Neurobiology of Learning and Memory, Spring Mtg. University of California, Irvine Invited by Dr. James L. McGaugh 3/99 Conference on Transgenic & Knock-­‐out Models of Alzheimer's Disease, UCLA Invited by Dr. Jeffery Cummings 10/99 University of California, Los Angeles Invited by Dr. Allan Tobin 11/00 University of Medicine and Dentistry of New Jersey Invited by Dr. Peter Frederikse 12/00 Neurogenetics Inc. Invited by Dr. Ken Stauderman 04/01 Dept. of Molecular Biology and Biochemistry; University of California, Irvine Invited by Dr. Edward Wagner 05/01 European Society for Neurochemistry; Perugia, Italy Invited by Dr. Gianfrancesco Goracci 07/01 Challenging Views on Alzheimer's Disease Cincinnati, OH Invited by Dr. Stephen R. Robinson (declined invitation) 09/01 Fading Memories —Saving Memories: Advances in Understanding Alzheimer’s Disease ‘Evenings to Remember’ Lecture Series Center for the Neurobiology of Learning and Memory University of California, Irvine Invited by Dr. James L. McGaugh 4/02 Neurogenetics, Inc. La Jolla, California Invited by Dr. Patricia P. Baskin 6/02 Praecis, Inc., Waltham, Massachusetts Invited by Dr. Mark Findeis 30
6/02 6/02 10/02 11/02 02/03 02/03 02/03 02/03 02/03 05/03 07/03 08/03 08/03 08/03 09/03 Department of Neuroscience, Tufts University School of Medicine Invited by Dr. Barbara Talamo New England Medical Center Invited by Dr. Henry Querfurth Case Western Reserve University Invited by Dr. Mark Smith Baylor University Invited by Dr. Hui Zheng Biogen, Inc. Invited by Dr. Colleen Mullen McGill University Invited by Dr. Claudio Cuello University of Southern California Invited by Dr. Austin Tang Mayo Clinic Jacksonville Invited by Dr. Todd Golde Orange County Alzheimer’s Association Invited by Linda Scheck, Executive Director California State University-­‐Los Angeles University of Catania (Italy) Invited by Dr. DiPinto Elan Pharmaceuticals (South San Francisco) Invited by Dr. Dale Schenck University of Rochester (New York) Invited by Dr. Howard Federoff Forest Research Institute (New York) Invited by Dr. Pradeep K. Banerjee Toccata Pharmaceuticals (Menlo Park, CA) Invited by Dr. Thomas Brennan 31
09/03 10/03 10/03 12/03 01/04 02/04 02/04 02/04 06/04 08/04 08/04 08/04 09/04 09/04 09/04 Johnson & Johnson Pharmaceuticals (PA) Invited by Dr. Kevin M. Felsenstein University Club, University of California, Irvine Town and Gown Presentation Loyola University (Chicago, IL) Invited by Dr. Benjamin Wolozin Oregon Health Sciences University (Portland, OR) Invited by Dr. Hemachandra Reddy Pfizer Pharmaceuticals, Inc. (Groton CT) Invited by Dr. Dane Liston Karolinska Institute (Stockholm, Sweden) Invited by Dr. Maria Anarcona Karolinska Institute (Stockholm, Sweden) Invited by Dr. Maria Anarcona La Sapienza University (Rome, Italy) Invited by Dr. Cuomo Bristol Myers Squibb (CT) Invited by Dr. Charles Albright Burnham Institute, San Diego (CA) Invited by Dr. Huaxi Xu Allergan Pharmaceuticals (Irvine, CA) Invited by Dr. Mitchell Brin University of Kentucky (Lexington) Invited by Dr. Joseph Berger Amgen Pharmaceuticals (Thousand Oaks, CA) Invited by Dr. Qiao Yan University of Manchester (UK) Invited by Dr. Alex Verkhratsky University of Leeds (UK) 32
10/04 10/04 11/04 01/05 02/05 03/05 03/05 03/05 04/05 10/05 10/05 11/05 11/05 Invited by Dr. Chris Peers Department of Pharmacology, UCI Invited by Dr. Frances Leslie Department of Biological Chemistry, UCI University of Texas-­‐Southwest (Dallas) Invited by Dr. Ilya Bezprozvanny University of California, San Francisco Invited by Dr. Lennart Mucke Emory University, Center for Neurodegenerative Disease Invited by Dr. Timothy Greenamyre Modeling and Treating Alzheimer’s Disease Orange County Alzheimer’s Association Founder’s Club Roche Palo Alto Invited by Dr. Sanja Novakovic Memory Pharmaceuticals, Inc. (Park Ridge, NJ) Invited by Dr. Jeffery Kogan University of Pennsylvania Invited by Dr. Domenico Pratico University of Alabama (Birmingham) Invited by Dr. Gail Johnson Columbia University Invited by Dr. Tae-­‐wan Kim Takeda Pharmaceuticals Osaka, Japan Universitat Autònoma de Barcelona Invited by Dr. Lydia Gimenez Llort 12/05 University of Washington Invited by Dr. David Cook 02/06 Scripps Research Institute (LaJolla, CA) 33
02/06 02/06 02/06 02/06 04/06 04/06 05/06 05/06 05/06 05/06 05/06 06/06 06/06 10/06 Invited by Dr. Mark Mayford National Institute of Aging (NIH, Bethesda, MD) Invited by Dr. Mark Cookson Rosalind Franklin University of Medicine and Science (Chicago) Invited by Dr. Grace Stutzmann Northwestern University (Chicago) Invited by Dr. John Disterhoft Allergan Lecture on Modern Biology Invited by Dr. Susan Bryant Boehringer Ingleheim, (Biberach, Germany) Invited by Dr. Cornelia Dorner-­‐Ciossek University of Zurich (Switzerland) Invited by Dr. Roger Nitsch UCI CEO Roundtable (Hawaii) Invited by Dr. Nancy Weintraub Pfizer (Groton, CT) Invited by Dr. Joel Schachter Dartmouth Medical College (Hanover, NH) Invited by Dr. T. Y. Chang Scripps Florida Invited by Dr. Malcolm Leissring Abbott Labs, Chicago Invited by Dr. Murali Gopalakrishnan Vertex Pharmaceuticals Invited by Dr. Heim University of California, Santa Barbara Invited by Dr. Ken Kosik Uppsala University, (Sweden) Invited by Dr. Lars Lannsfelt 34
10/06 Astra-­‐Zeneca Alzheimer’s Disease Symposium 2006, Stockholm, Sweden Invited by Drs. Ratan Bhat and Samantha Budd 10/06 Setting the Alzheimer Research Agenda 100 years after Auguste D., NIA, Bethesda, MD Invited by Dr. Neil Buckholtz 11/06 University of North Texas Health Sciences Center Invited by Dr. Michael Forester 02/07 University of Houston (Houston, TX) Invited by Dr. Karim Alkadhi 03/07 Fondazione Universita “Gabriele d’Annuzio” and Centro di Eccellenza sull’invecchiamento (Pescara, Italy) Invited by Dr. Stefano Sensi 10/07 University of Pennsylvania Invited by Dr. Kevin Foskett 11/07 Targeted Genetics Corp. (Seattle, WA) Invited by Dr. Richard Peluso 3/08 Abbott Labs (Lake Forest, IL) Invited by Dr. Murali Gopalakrishnan 4/08 Harvard University Invited by Dr. Dennis Selkoe 4/08 Jan Swammerdam Lecture Netherlands Institute for Neuroscience (Amsterdam) Invited by Dr. Elly Hol 5/08 MIT Invited by Dr. Li-­‐Huei Tsai 12/08 California Independent Citizens Oversight Committee Invited by Dr. Maria Csete 1/09 University of Alabama at Birmingham Invited by Dr. Jianhua Zhang 1/09 CIRM Invited by Dr. Maria Csete 35
2/09 Geron Corp. Invited by Dr. Jane Lebkowski 6/09 University of Illinois, Chicago Invited by Dr. Orli Lazarov 6/09 CIRM Invited by Dr. Maria Csete 6/09 Medtronics Neuromodulation (Minneapolis) Invited by Dr. Jack Keimel 07/09 Signum Biosciences Invited by Dr. Greg Stock 09/09 University of Oklahoma Health Sciences Center Invited by Graduate Students 11/09 National Institute on Aging (NIH, Bethesda, MD) Invited by Dr. Francesca Bosetti 5/10 Temple University, Philadelphia Invited by Dr. Domenico Pratico 9/10 University of Tennessee Health Science Center Invited by Dr. Michael McDonald 9/10 University of North Dakota, School of Medicine & Health Sciences Invited by Dr. Jonathan Geiger 4/11 University of Colorado, Aurora Invited by Dr. John Sladek 6/12 Norman Prince Neuroscience Symposium, Brown University Invited by Dr. John Robson Oral Presentations at Professional Meetings: 10/93 Transgenic Animal Models of Human Diseases American College of Toxicology Annual Meeting, New Orleans Session Chairman: Dr. Stanley Roberts 36
5/95 3/99 Apoptotic Cell Death in Neurodegenerative Disorders Eighth Sardinian Conference on Neuroscience Cagliari, Sardinia (Italy) Aß Transgenic Models Conference on Transgenic & Knock-­‐out Models of Alzheimer's Disease University of California, Los Angeles 4/00 Calcium Signaling Changes as a Consequence of Mutations in Presenilin-­‐1 and -­‐2 Common Mechanisms of Neurodegenerative Disorders, Tobago 4/00 Session Chair: Neurotoxic Mechanisms: Calcium and Glutamate Common Mechanisms of Neurodegenerative Disorders, Tobago 11/00 Modulation of Calcium Signaling by Presenilin Mutations Society for Neuroscience, New Orleans, LA 11/00 Do Mutations in Alpha-­‐Synuclein Disrupt Intracellular Calcium Signaling? Society for Neuroscience, New Orleans, LA 6/01 Gamma-­‐secretase-­‐mediated Modulation of Calcium Signaling American Aging Association 30th Annual Meeting, Madison, WI 7/02 A Physiologic Signaling Role for the Gamma-­‐secretase Derived Intracellular Fragment of APP 8th International Conference on Alzheimer’s disease and Related Disorders 8/02 A Novel Triple Transgenic Model of Alzheimer's Disease 5th International Conference on Antioxidants and Free Radicals, Vancouver, BC 10/02 3rd Neurobiology of Aging Conference: Molecular and Cellular Basis of Synaptic Loss and Dysfunction in Alzheimer’s Disease 01/03 A Physiologic Signaling Role for the APP Intracellular Domain Winter Conference on Brain Research, Snowbird UT 05/03 Triple Transgenic Model of Alzheimer’s Disease Sixth International AD/PD meeting, Seville, Spain 06/03 Organizer and Speaker, Advances in Inclusion Body Myositis National Conference University of California, Irvine 11/03 Triple Transgenic Model of Alzheimer’s Disease with Plaques and Tangles: Intracellular Aß and Synaptic Dysfunction 37
Society for Neuroscience, New Orleans, LA 11/03 AICD Governs Expression of an ER Calcium Pump: A Mechanistic Link Between Intranuclear Signaling, Aß, and Calcium Society for Neuroscience, New Orleans, LA 04/04 Symposium on Role of Calcium Signaling in Mental Disorders Society for Biological Psychiatry, New York, NY Invited by Dr. Michael S. Lidow 04/04 Amyloid ß-­‐peptide and Cognitive Decline in Alzheimer’s Disease: The Inside Story Center for the Neurobiology of Learning and Memory Symposium on New Developments in Gene/Behavior Interface 20th Annual Spring Meeting 05/04 Alzheimer’s Association of Orange County Symposium on Experience of Alzheimer’s Disease: Enrichment Paradigms 07/04 Institute for the Study of Aging: Aiming for Mechanism-­‐based Models of Alzheimer's Disease Invited by Dr. Peter Davies. 07/04 9th International Conference on Alzheimer’s Disease & Related Disorders, Philadelphia 08/04 7th International Conference on Protective Strategies for Neurodegenerative Diseases Vancouver, Canada Invited by Dr. Debomoy Lahiri 09/04 Assessing Cognition for Emerging Therapeutics in AD Invited by Dr. Marilyn Alberts and Michela Gallagher 11/04 Degenerative Disorders of Aging; Gerontological Society of America Meeting, Invited by Dr. Monica Driscoll 03/05 Seventh International AD/PD Meeting, Sorrento, Italy Invited by Dr. Abraham Fisher 04/05 Biology of Tau Symposium; ADC Director’s Meeting Miami, FL 06/05 UCLA Symposium on Learning and Memory Invited by Dr. Alcino Silva 11/05 First International Symposium on Geriatrics and Gerontology, Nagoya, Japan 38
11/05 11/05 03/06 04/06 Invited by Dr. Takeshi Tabira Aging and Neurodegeneration (Satellite Symposium) Washington DC Invited by Dr. Michael Forster Symposium Lecture on Tau Biology Society for Neuroscience, Washington, DC Organized by Dr. Gail Johnson 8th Conference on the Neurobiology of Learning and Memory Irvine, CA Invited by Dr. Michael Rugg Reversing Age-­‐dependent Memory Deficits in a Transgenic Model of AD 9th International Symposium on Advances in Alzheimer Therapies (Geneva, Switzerland) Invited by Dr. Ezio Giaccobini 05/06 Plasticity and Repair in Neurodegenerative Disorders (Lake Arrowhead) Invited by Drs. Michael Jakowec, Bruce Teter, Mark Lew, & Giselle Petzinger 07/06 International Conference on Alzheimer Disease Invited by Dr. Khalid Iqbal 10/06 Neurotoxic Mechanisms in Alzheimer Disease, Atlanta, GA Invited by Lary Walker and Richard M. Kostrzewa 10/06 ICREA Brain Research Conference Barcelona, Spain Invited by Drs. Elena Galea and Carlos Saura 12/06 Multiple Targets for Alzheimer’s Disease: γ-­‐secretase and tau Topic: Mechanisms by Which Aß Facilitates Tau Pathology New York Academy of Sciences Invited by Drs. Donna Barten, Barbara Tate, and Barbara Petrack 03/07 8th International AD/PD Conference Invited by Dr. Abraham Fisher 05/07 Strategies for Improving the Cognitive and Neuropathological Phenotype in AD Mice John Theobald Memorial Lecture Arizona Alzheimer’s Consortium, Phoenix, AZ Invited by Dr. Eric Reiman 39
08/07 Modeling and Studying Alzheimer Disease in Mice and its Translation to Humans Life Science Symposium, Lausanne, Switzerland Invited by Dr. Pierre Magistretti 09/07 NIA Advisory Workshop on Animal Models of Comorbidities in Aging Invited by Dr. Evan Hadley 09/07 GTCbio’s 3rd Therapeutic Strategies against Neurodegenerative Conditions Conference Invited by Ms. Christy Bowman 2/08 Calcium in Neurodegeneration Hereditary Disease Foundation/Lou Ruvo Brain Institute (Las Vegas) Invited by Drs. Nancy Wexler and Carl Johnson 2/08 From Molecules to Mind: Role of HPA in CNS disease and consequences of dysregulated peripheral feedback New York Academy of Sciences Invited by Dr. David Riddell 2/08 10th International Hong Kong/Springfield Pan-­‐Asian Symposium on AD Treatment Invited by Dr. Ezio Giacobini 3/08 Keystone Symposium on Alzheimer’s Disease Invited by Dr. David Holtzman 6/08 11th Annual UCLA Learning and Memory Conference Invited by Dr. Alcino Silva 7/08 Plenary Lecture: Mouse Models of Alzheimer’s Disease International Conference on Alzheimer’s Disease Invited by Dr. Khalid Iqbal and Bengt Wingblad 3/09 9th Annual AD/PD Conference, Prague Invited by Dr. Abraham Fisher 3/09 7th Annual Mild Cognitive Impairment Symposium, Miami Invited by Ranjan Duara 4/09 Spring Brain Conference, Palm Springs Invited by Dr. Richard Robertson 4/09 From Molecular Biology to Human Therapies: Strategies, Challenges, and Opportunities The Beckman Center, UCI, Invited by Dr. Nancy Weintraub 40
5/09 11/09 12/09 1/10 7/10 7/10 9/10 11/10 1/11 3/11 3/11 3/11 3/11 5/11 100th Annual AOCS Invited by Dr. Eileen Bailey Hall Gerontological Society of America Invited by Dr. George Martin Third International Brain Conference (Orlando FL) Invited by Kiminobu Sugaya Biology of Tau Conference (UK Biochemical Society, Cambridge, England) Invited by Drs. Amrit Mudher and Makis Skoulakis Alzheimer’s Imaging Consortium (AIC), Honolulu, Hawaii Invited by Drs. Sandra Black and Giovanni Frisoni International Conference on Alzhiemer’s Disease Invited by Dr. Khalid Iqbal Frontiers in Cell Biology & Medicine, York University, U.K. Invited by Dr. Jo. Milner AHAF Update on Alzheimer Research: Workshop for Ph.D. Students (San Diego) Invited by Anja de Bruin Keystone Symposium on Neurogenesis (Taos, NM) Invited by Dr. Fred Gage International AD/PD Meeting (Barcelona, Spain) Invited by Dr. Abraham Fisher Southern California Symposium on Alzheimer’s Disease (UCLA) Invited by Dr. John Ringman Keynote Address: Lou Ruvo Institute, Las Vegas Invited by Dr. Jeffery Cummings Gladstone Institute/DZBE: Tau and Tau Pathogenic Mechanisms Invited by Dr. Lennart Mucke Neural Therapy & Repair Meeting, Clearwater, FL Invited by Dr. Oswald Steward 41
7/11 International Congress on Alzheimer’s Disease, Paris, France Invited by Nicole Sanders 10/11 Nathan Shock Center Conference on Aging, Bandera Texas Invited by Dr. Yuji Ikeno 11/11 Advances in Neuroscience for Medical Innovation, Cap Ferrat, France Invited by Dr. Michael Spedding 10/12 AHAF Alzheimer’s Disease Workshops, New Orleans,LA Invited by Dr. H. Steinbusch ADMINISTRATIVE SERVICE: SERVICE TO THE UNIVERSITY: 2010 Member, Search Committee for Assistant Vice Chancellor of OTA 2009-­‐present Leadership Council on Regenerative Medicine 2008-­‐2009 Member, Search Committee for Chair of Neurology 2007-­‐2008 Member, Office of Technology Alliance Review Committee 2007-­‐present Member, Animal Research Advisory Committee (ARAC) 2006 Member, Search Committee for Chair of Anatomy & Neurobiology 2003-­‐2007 Director, Interdepartmental Neuroscience Program 2003-­‐present Member, Gillespie Vivarium Expansion Committee 2003-­‐present Vivarium Master Planning Committee 2002 Committee to Develop Interdepartmental Neuroscience Program 2001-­‐2003 Voting Member, Institutional Animal Care and Use Committee 1999-­‐2005 Medical-­‐Scientist Training Program Admissions Committee 2001-­‐2005 Campus Animal Facilities Committee 1999-­‐2001 Member, Irvine Academic Senate Division 1999 Faculty Search Committee, Reeve-­‐Irvine Spinal Cord Research Center 1997-­‐1998 Neuroscience Website Committee 1996-­‐2001 Faculty Advising, Undeclared/Undecided Majors 1998-­‐2000 Advisory Group, Irvine Chapter of the Society for Neuroscience SERVICE TO THE SCHOOL OF BIOLOGICAL SCIENCES: 2008-­‐present Member, Capital Campaign 2006-­‐2007 Member, Dean of Biological Sciences Search Committee 2003-­‐2004 Member, Biological Sciences-­‐3 Building Advisory Planning Committee 2000-­‐present Member, Dean’s Intellectual Property Discussion Group 1999-­‐2001 Member, Executive Committee of School of Biological Sciences 42
1997-­‐2000 1998 1998 1996-­‐1997 SERVICE TO THE DEPARTMENT: 2006-­‐present 2003 2003 2002 2002 2001-­‐present 2001 2001-­‐2002 1998-­‐1999 2000-­‐2001 1997-­‐2000 1997-­‐2000 1997-­‐1998 1997 SERVICE TO ORGANIZED RESEARCH UNITS: •Institute for Memory Impairments and Neurological Disorders -­‐Director -­‐Member of the Executive Committee -­‐Coordinator of Institute Seminar Program Undergraduate Cabinet Career Workshop Natural Sciences Building Planning Committee Biological Sciences Student Health Issues Faculty Mentoring Committee Executive Committee, Interdisciplinary Neuroscience Program Faculty Search Committee (Assistant Prof.), Neurobiology & Behavior Chair, Assistant Professor Search Committee Interdepartmental Neuroscience Planning Group Graduate Core Curriculum Oversight Committee Graduate Core Curriculum Development Committee Department Training Grant Committee Neurobiology and Behavior Chair Search Committee Faculty Search Committee (Assistant Prof.), Neurobiology & Behavior Faculty Search Committee, (Senior Neurologist) Coordinator, Department Colloquium Series Graduate Admissions Committee Department Brochure Committee •Center for the Neurobiology of Learning and Memory -­‐Fellow -­‐Executive Committee (2007-­‐present) -­‐Member, Search Committee for New Director (2010) -­‐Organizing Committee for the CNLM 2001 Spring Meeting -­‐Membership Committee SCIENTIFIC ADVISORY BOARD: 2007-­‐present Sonexa Therapeutics, Inc. (LaJolla, CA) 2007-­‐present American Federation of Aging Research 2007-­‐present Scientific Advisory Board, International AD/PD Conference 2008 International Conference on AD Scientific Board Committee 43
2003-­‐2006 Toccata Therapeutics, Inc. (Menlo Park, CA) COMMUNITY SERVICE: Member, Board of Directors, Orange County Alzheimer’s Association (2007-­‐present) Advisor, Orange Coast College, Biotechnology Certificate Program, 2000, 2002 TEACHING: UNDERGRADUATE COURSES: •Neurogenetics, N162 (1997 – present, odd years) •Introduction to Neurobiology & Behavior, BioSci #110 (1996-­‐2001) •Neuroscience Fundamentals, N112A (2001-­‐present) •Freshmen Seminar: Neurobiology of Disease (2003-­‐present) GRADUATE COURSES: •Synaptic, Cellular, and Molecular Neurobiology, BioSci #210 (1999, 2000, -­‐01) •Advanced Topics in Neurogenetics, BioSci #268 (1998, 2000, -­‐01) •Molecular Neuroscience, BioSci #206 (2002-­‐07) GRADUATE STUDENTS SUPERVISED: PH.D. STUDENTS (COMPLETED): 1. Malcolm A. Leissring (1996-­‐2000), awarded Ph.D. June 2000 Dissertation: Modulation of Calcium Signaling by Alzheimer’s Presenilin Mutations Current Position: Assistant Professor, Mayo Clinic Jacksonville 2. Michael C. Sugarman (1997-­‐2002), awarded Ph.D. June 2002 Dissertation: Transgenic Mouse Model of Inclusion Body Myositis Current Position: Research Scientist, Diagnostic BioSystems 3. Yama Akbari (1999-­‐2005), awarded Ph.D January 2005 Dissertation: Modulation of ß-­‐amyloid Production through Calcium Signaling Alterations Current Position: Assistant Professor of Neurology, UC Irvine 4. Salvatore Oddo (2002-­‐2005), awarded Ph.D. June 2005 Dissertation: Aß and Tau Interactions in a Transgenic Model of Alzheimer’s Disease Current Position: Associate Professor, Univ. of Texas Health Sciences Ctr, San Antonio 44
5. 6. 7. 8. 9. 10. 11. Bert Tseng (2001-­‐2006), awarded Ph.D. May 2006 Dissertation: Aß Mediated Dysfunction of the Ubiquitin-­‐Proteasome System Facilitates the Pathological Accumulation of Alzheimer Disease Proteins Aß and Tau Current Position: Medical Resident, UC Irvine Tritia R. Yamasaki (2002-­‐2007), awarded Ph.D May 2007 Dissertation: Neural Stem Cells Improve Cognition in an Inducible Mouse Model of Neuronal Loss Current Position: Neurology Resident, UC Irvine Lani Clinton, Ph.D. student (2004 – 2007), awarded Ph.D. June 2007 Dissertation: Synergistic Interactions among Aß, Tau, and a-­‐synuclein: Acceleration of Neuropathology and Cognitive Decline Current Position: Medical Student, University of Hawaii Debbie Morrissette, Ph.D. student (2003-­‐2009), awarded Ph.D. June 2009 Dissertation: Effects of mouse genetic background strain on Alzheimer-­‐like pathology and behavior in the 3xTg-­‐AD mouse model of Alzheimer’s disease Current Position: Adjunct Assistant Professor, Cal State University, San Marcos Michael Sy, M.D./Ph.D. student (2002-­‐2009), awarded Ph.D. June 2009 Dissertation: Chronic inflammation induces tau phosphorylation and cognitive impairments in the 3xTg-­‐AD mouse model Current Position: Neurology Resident, UC Irvine Maya Koike, Ph.D. (2006-­‐2010), awarded Ph.D. December 2010 Dissertation: Cerebral hypoperfusion and Alzheimer’s disease: studies in mouse models Current Position: Postdoctoral Fellow, University of Pennsylvania Kara M. Neely, Ph.D. student (2007-­‐2011) Dissertation: Role of autophagy in Alzheimer disease Current Position: Veterinary Medicine Student Current Ph.D. Students (in progress): 1. Kris Myczek, Ph.D. student (2007 – present) Topic: Functional Role of Neurogenesis in Learning and Memory 2. Nicholas Castello, Ph.D. student (2008 – present) Topic: Role of BDNF in AD 45
3. Meredith Chabrier, Ph.D. student (2009-­‐present) Topic: Novel mouse models of Alzheimer disease MASTER’S STUDENTS: Libby Weber (1996-­‐1998) Steven Hinton (1998-­‐2000) ASSISTANT PROFESSORS/RESEARCHERS SUPERVISED Kim Green, Ph.D., Assistant Professor in Residence (08/03 – present) Interests: Factors that modulate Aß and tau pathology Masashi Kitazawa, Ph.D., Project Scientist (02/03 – present) Interests: Transgenic models of inclusion body myositis Jack Reidling, Ph.D. Associate Project Scientist Current Interests: Exploring relationships between aging and associated Alzheimer’s disease related pathologies and the absorption of the vitamin thiamine Kristine Freude, Ph. D. Assistant Project Scientist Interests: establishment of novel in vitro models of AD using human embryonic stem cells and to examine the role of APP in neuronal differentiation Mathew Blurton-­‐Jones, Ph.D., Assistant Researcher(08/05-­‐ present) Interests: Neural stem cells as treatments for neurodegenerative disorders Hilda Martinez-­‐Coria, D.V.M., Ph.D., Assistant Project Scientist (08/06 – present) Interests: Learning and its impact on AD pathology CURRENT POSTDOCTORAL RESEARCHERS: Rodrigo Mederios, Ph.D. (6/08-­‐present) Interests: Inflammation David Baglietto-­‐Vargas, Ph.D. (3/09-­‐present) Interests: Biomarker for Alzheimer’s disease K. C. Walls, Ph.D. (6/09-­‐present) Interests: Autophagy and Alzheimer’s disease 46
Rahasson Ager, Ph. D. 06/10 – present) Interests: Developing an optimal immunosuppression regimen for the successful engraftment of human neuronal stem cells into mouse models of AD FORMER POSTDOCTORAL RESEARCHERS: 1. Malcolm Leissring, Ph.D. (6/00 – 5/01) Current Position: Assistant Professor, Mayo Clinic Jacksonville Florida 2. Mehrdad Jannatipour, Ph.D. (4/01 – 4/02) Current Position: Scientist, Focus Technologies, CA 3. Karen L. Nowak, Ph.D. (08/01-­‐04/03) Current Position: Neuroscience Medical Science Liaison, Bristol-­‐Myers Squibb 4. Karah Street, Ph.D. (09/01-­‐08/03) Current Position: Assistant Professor, Saddleback College 5. Grace Stutzmann, Ph.D. (09/01 – 08/03) Current Position: Associate Professor, Rosalind Franklin Medical School (Chicago, IL) 6. Lauren Billings, Ph.D. (07/03 – 11/05) Current Position: Scientist, Allergan Pharmaceuticals, Irvine 7. Ian Smith, Ph.D. (02/03 – 02/07) Current Position: Project Scientist, UCI 8. Salvatore Oddo, Ph.D. (06/05 -­‐ 06/08) Current Position: Assistant Professor, University of Texas HSC, San Antonio 9. Anna Parachikova, Ph.D. (01/07-­‐07/08) Current Position: Lundbeck Pharmaceuticals 10. Carlos Rodriguez-­‐Ortiz, Ph. D. (01/10-­‐ 02/12) Current Position: Postdoctoral Fellow, UC Merced 47

Alzheimer’s Drugs Market

Anti-β-Alzheimer Therapies Market Scrutinized in New Research 2018-2026

Alzheimer’s Drugs Market Consumption Analysis By Latest Trend, Drivers And Challenges 2025

Alzheimers Diagnostic Test Market Research Report 2018-2025 Forecast

program.pdf

Neuroscience Market Release Latest Trends and Industry Vision 2026

Brain Monitoring Market

information on this model

Neuroscience Market